The JAK1 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting JAK1 in the human CAL-27 tongue squamous cell carcinoma line. This loss-of-function model allows pooled functional studies of JAK1-dependent signaling without clonal selection artifacts.
The CAL-27 cell line originates from a poorly differentiated tongue squamous cell carcinoma of a 56-year-old male and is a standard in vitro model for oral squamous cell carcinoma. Its neoplastic epithelial characteristics make it valuable for studying carcinogenesis, metastatic progression, and therapy resistance.
JAK1 encodes a non-receptor tyrosine kinase that transduces signals from type I and type II cytokine receptors. It is activated by upstream ligands such as interleukin-6 (IL-6), interferon-gamma (IFN-??), and interleukin-2 (IL-2), and associates with receptor subunits including gp130, IL-6R??, IFNAR1, and IL-2R??. Upon activation, JAK1 phosphorylates receptor tyrosines, enabling recruitment and phosphorylation of downstream STAT3, STAT1, and STAT5 transcription factors. Dimerized STATs translocate to the nucleus and regulate gene expression, a process negatively controlled by SOCS3 and PIAS proteins. The JAK1-STAT3 module, together with JAK2, PTPN11, and ERK, mediates cellular responses in proliferation, differentiation, and immunity.
In the CAL-27 oral cancer context, JAK1 disruption abrogates signaling downstream of multiple cytokines, providing a system to dissect how JAK-STAT activity influences tumor progression. Aberrant IL-6/gp130/STAT3 signaling is implicated in oral squamous cell carcinoma growth, survival, and immune escape. This knockout model enables interrogation of autocrine and paracrine cytokine dependencies and compensatory kinase networks in a disease-relevant background.
Applications include Western blot and RT-qPCR analysis of JAK1 and STAT3 targets, IL-6 stimulation assays to probe cytokine responsiveness, MTT proliferation and Transwell migration assays to assess tumor cell behavior, and Annexin V apoptosis assays. The polyclonal knockout population also supports JAK inhibitor sensitivity screening and functional studies of immune evasion and drug resistance. For technical inquiries, contact Ascent Research.
